MA52090A - Polythérapie - Google Patents
PolythérapieInfo
- Publication number
- MA52090A MA52090A MA052090A MA52090A MA52090A MA 52090 A MA52090 A MA 52090A MA 052090 A MA052090 A MA 052090A MA 52090 A MA52090 A MA 52090A MA 52090 A MA52090 A MA 52090A
- Authority
- MA
- Morocco
- Prior art keywords
- polytherapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862646314P | 2018-03-21 | 2018-03-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA52090A true MA52090A (fr) | 2021-04-21 |
Family
ID=67988025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA052090A MA52090A (fr) | 2018-03-21 | 2019-03-20 | Polythérapie |
Country Status (16)
Country | Link |
---|---|
US (1) | US20210000838A1 (fr) |
EP (1) | EP3768258A4 (fr) |
JP (1) | JP2021517116A (fr) |
KR (1) | KR20200135439A (fr) |
CN (1) | CN112165939A (fr) |
AU (1) | AU2019238207A1 (fr) |
BR (1) | BR112020019082A2 (fr) |
CA (1) | CA3093847A1 (fr) |
EA (1) | EA202092154A1 (fr) |
IL (1) | IL277336A (fr) |
MA (1) | MA52090A (fr) |
MX (1) | MX2020009773A (fr) |
SG (1) | SG11202009137PA (fr) |
TW (1) | TW202002983A (fr) |
WO (1) | WO2019183226A1 (fr) |
ZA (1) | ZA202005661B (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2608742C2 (ru) | 2011-03-28 | 2017-01-23 | ЭмИАй ФАРМА, ИНК. | (альфа-замещенные аралкиламино- и гетероарилалкиламино)пиримидинил- и 1, 3, 5-триазинилбензимидазолы, их фармацевтические композиции и их применение в лечении пролиферативных заболеваний |
WO2015035606A1 (fr) | 2013-09-13 | 2015-03-19 | Beigene, Ltd. | Anticorps anti-pd1 et leur utilisation comme produits thérapeutiques et produits de diagnostic |
EP3160505A4 (fr) | 2014-07-03 | 2018-01-24 | BeiGene, Ltd. | Anticorps anti-pd-l1 et leur utilisation comme agents thérapeutiques et diagnostiques |
NZ751418A (en) | 2016-08-16 | 2023-04-28 | Beigene Ltd | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
CA3034326A1 (fr) | 2016-08-19 | 2018-02-22 | Beigene, Ltd. | Utilisation d'une combinaison comprenant un inhibiteur de btk pour le traitement de cancers |
WO2018217787A1 (fr) | 2017-05-23 | 2018-11-29 | Mei Pharma, Inc. | Polythérapie |
KR20200020902A (ko) | 2017-06-26 | 2020-02-26 | 베이진 엘티디 | 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료 |
EP3668507A4 (fr) | 2017-08-14 | 2021-05-12 | MEI Pharma, Inc. | Polythérapie |
WO2019108795A1 (fr) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Traitement de lymphomes à cellules b indolentes ou agressives au moyen d'une combinaison comprenant des inhibiteurs de btk |
US20220249491A1 (en) * | 2019-06-10 | 2022-08-11 | Beigene Switzerland Gmbh | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor |
CN113950327A (zh) * | 2019-06-10 | 2022-01-18 | 百济神州瑞士有限责任公司 | 口服胶囊剂及其制备方法 |
CN110922409A (zh) * | 2019-12-19 | 2020-03-27 | 武汉九州钰民医药科技有限公司 | 制备btk抑制剂泽布替尼的方法 |
KR20210115375A (ko) * | 2020-03-12 | 2021-09-27 | 보령제약 주식회사 | Pi3 키나아제 저해제 및 btk 저해제를 포함하는 조성물 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2608742C2 (ru) * | 2011-03-28 | 2017-01-23 | ЭмИАй ФАРМА, ИНК. | (альфа-замещенные аралкиламино- и гетероарилалкиламино)пиримидинил- и 1, 3, 5-триазинилбензимидазолы, их фармацевтические композиции и их применение в лечении пролиферативных заболеваний |
US20160287592A1 (en) * | 2013-04-08 | 2016-10-06 | Pharmacyclics Llc | Ibrutinib combination therapy |
KR20160093062A (ko) * | 2013-12-05 | 2016-08-05 | 아세르타 파마. 비.브이. | Pi3k 억제제 및 btk 억제제의 치료적 조합 |
TW201613644A (en) * | 2014-06-17 | 2016-04-16 | Acerta Pharma Bv | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor |
US20170231995A1 (en) * | 2014-08-11 | 2017-08-17 | Acerta Pharma B.V. | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment |
-
2019
- 2019-03-20 CN CN201980034008.0A patent/CN112165939A/zh active Pending
- 2019-03-20 JP JP2020545770A patent/JP2021517116A/ja active Pending
- 2019-03-20 BR BR112020019082-9A patent/BR112020019082A2/pt not_active IP Right Cessation
- 2019-03-20 AU AU2019238207A patent/AU2019238207A1/en not_active Abandoned
- 2019-03-20 EA EA202092154A patent/EA202092154A1/ru unknown
- 2019-03-20 US US16/981,780 patent/US20210000838A1/en not_active Abandoned
- 2019-03-20 MA MA052090A patent/MA52090A/fr unknown
- 2019-03-20 CA CA3093847A patent/CA3093847A1/fr active Pending
- 2019-03-20 WO PCT/US2019/023172 patent/WO2019183226A1/fr unknown
- 2019-03-20 KR KR1020207030110A patent/KR20200135439A/ko not_active Application Discontinuation
- 2019-03-20 SG SG11202009137PA patent/SG11202009137PA/en unknown
- 2019-03-20 MX MX2020009773A patent/MX2020009773A/es unknown
- 2019-03-20 EP EP19770484.4A patent/EP3768258A4/fr not_active Withdrawn
- 2019-03-21 TW TW108109853A patent/TW202002983A/zh unknown
-
2020
- 2020-09-11 ZA ZA2020/05661A patent/ZA202005661B/en unknown
- 2020-09-14 IL IL277336A patent/IL277336A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2021517116A (ja) | 2021-07-15 |
WO2019183226A1 (fr) | 2019-09-26 |
KR20200135439A (ko) | 2020-12-02 |
CA3093847A1 (fr) | 2019-09-26 |
TW202002983A (zh) | 2020-01-16 |
EA202092154A1 (ru) | 2021-03-22 |
EP3768258A1 (fr) | 2021-01-27 |
BR112020019082A2 (pt) | 2020-12-29 |
IL277336A (en) | 2020-10-29 |
SG11202009137PA (en) | 2020-10-29 |
US20210000838A1 (en) | 2021-01-07 |
ZA202005661B (en) | 2023-05-31 |
CN112165939A (zh) | 2021-01-01 |
MX2020009773A (es) | 2020-10-08 |
AU2019238207A1 (en) | 2020-10-01 |
EP3768258A4 (fr) | 2022-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52090A (fr) | Polythérapie | |
MA47676A (fr) | Polythérapie | |
MA46285A (fr) | Polythérapie | |
MA49921A (fr) | Polythérapie | |
MA56057A (fr) | Polythérapie | |
DK3752258T3 (da) | Trampolin | |
DK3587968T3 (da) | Fluidsystem | |
MA49925A (fr) | Claie | |
DE112019000442A5 (de) | Ringtilgereinrichtung | |
NO20181678A1 (no) | Rissanviser | |
JP1628555S (ja) | たい焼 | |
JP1628556S (ja) | たい焼 | |
ES1218724Y (es) | Terrario | |
ES1224156Y (es) | Ecobolsera | |
UA38633S (uk) | Електролобзик | |
UA38598S (uk) | Пневмофарбопульт | |
UA38836S (uk) | Термокухоль | |
UA38581S (uk) | Термокухоль | |
UA38585S (uk) | Електролобзик | |
UA38632S (uk) | Електролобзик | |
UA38411S (uk) | Термокухоль | |
UA38582S (uk) | Термокухоль | |
UA38612S (uk) | Електролобзик | |
UA38602S (uk) | Термокухоль | |
UA38606S (uk) | Електролобзик |